Biophytis Unveils Phase 2 Obesity Trial Strategy for BIO101
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, drug-development, biotechnology
TL;DR
Biophytis is rolling out its Phase 2 obesity trial plan for BIO101, announced Sept 1, 2025.
AI Summary
Biophytis S.A. announced its Phase 2 obesity trial strategy for its drug candidate BIO101 on September 1, 2025. The company is based in Paris, France, and its principal executive office is located at Sorbonne University.
Why It Matters
This filing details Biophytis' strategic approach to testing BIO101 in obesity patients, which could impact the future development and potential market entry of this drug candidate.
Risk Assessment
Risk Level: medium — The filing concerns a clinical trial strategy, which carries inherent risks related to drug development success and regulatory approval.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- BIO101 (drug_candidate) — Subject of Phase 2 trial
- Stanislas Veillet (person) — Contact person
- September 1, 2025 (date) — Date of press release
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release issued by Biophytis S.A. on September 1, 2025, detailing its Phase 2 obesity trial strategy for BIO101.
When was the press release regarding the obesity trial strategy issued?
The press release was issued on September 1, 2025.
What is the name of the drug candidate being discussed?
The drug candidate being discussed is BIO101.
Where is Biophytis S.A. located?
Biophytis S.A. is located in Paris, France, with its principal executive office at Sorbonne University.
Does Biophytis S.A. file annual reports under Form 20-F or 40-F?
Biophytis S.A. indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 243 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2025-09-02 11:05:44
Filing Documents
- tm2525001d1_6k.htm (6-K) — 9KB
- tm2525001d1_ex99-1.htm (EX-99.1) — 17KB
- tm2525001d1_ex99-1img01.jpg (GRAPHIC) — 7KB
- 0001104659-25-086148.txt ( ) — 37KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOPHYTIS S.A. Date: September 2, 2025 By: /s/ Stanislas Veillet Name: Stanislas Veillet Title: Chairman and Chief Executive Officer